Cover Image

Design, Synthesis, and Evaluation of Niclosamide Analogs as Therapeutic Agents for Enzalutamide-Resistant Prostate Cancer

Niclosamide effectively downregulates androgen receptor variants (AR-Vs) for treating enzalutamide and abiraterone-resistant prostate cancer. However, the poor pharmaceutical properties of niclosamide due to its solubility and metabolic instability have limited its clinical utility as a systemic tre...

Full description

Saved in:

Bibliographic Details
Main Authors:	Borui Kang (Author), Madhusoodanan Mottamal (Author), Qiu Zhong (Author), Melyssa Bratton (Author), Changde Zhang (Author), Shanchun Guo (Author), Ahamed Hossain (Author), Peng Ma (Author), Qiang Zhang (Author), Guangdi Wang (Author), Florastina Payton-Stewart (Author)
Format:	Book
Published:	MDPI AG, 2023-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Fulvestrant-3-Boronic Acid (ZB716) Demonstrates Oral Bioavailability and Favorable Pharmacokinetic Profile in Preclinical ADME Studies
by: Jiawang Liu, et al.
Published: (2021)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
by: Rodriguez-Vida A, et al.
Published: (2015)

Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis
by: Peng-Fei Zhang, et al.
Published: (2021)

Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer
by: Semenas J, et al.
Published: (2013)

Prostate-specific membrane antigen targeted, glutathione-sensitive nanoparticles loaded with docetaxel and enzalutamide for the delivery to prostate cancer
by: Yang Chen, et al.
Published: (2022)

Advanced prostate cancer – patient survival and potential impact of enzalutamide and other emerging therapies
by: Patel NK, et al.
Published: (2014)

A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer
by: Yan Li, et al.
Published: (2022)

Pharmacist-Urologist Collaborative Management Improves Clinical Outcomes in Patients With Castration-Resistant Prostate Cancer Receiving Enzalutamide
by: Masaki Hirabatake, et al.
Published: (2022)

Enzalutamide-induced signatures revealed by epigenetic plasticity using single-cell multi-omics sequencing in prostate cancer
by: Huihui Fan, et al.
Published: (2023)

Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2019)

Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide
by: Yi-Ting Lin, et al.
Published: (2021)

Effect of N-methyl deuteration on metabolism and pharmacokinetics of enzalutamide
by: Jiang J, et al.
Published: (2016)

Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models
by: Pengfei Xu, et al.
Published: (2023)

Novel MDM2 Inhibitor XR-2 Exerts Potent Anti-Tumor Efficacy and Overcomes Enzalutamide Resistance in Prostate Cancer
by: Meng Wu, et al.
Published: (2022)

Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
by: N. K. Mazina, et al.
Published: (2017)

Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis
by: Xin Wang, et al.
Published: (2020)

Discovery of a highly potent and orally available importin-β1 inhibitor that overcomes enzalutamide-resistance in advanced prostate cancer
by: Jia-Luo Huang, et al.
Published: (2023)

Indirect Spectrophotometric Determination of Niclosamide in Pharmaceutical Preparations
by: Nabeel S. Othman, et al.
Published: (2018)

Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?
by: Ming-kun Chen, et al.
Published: (2022)

Repurposing Niclosamide as a Therapeutic Drug against Acute Liver Failure by Suppressing Ferroptosis
by: Xiao Zhong, et al.
Published: (2023)

Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells
by: Namrata Khurana, et al.
Published: (2020)

Ethacrynic acid is an inhibitor of human factor XIIIa
by: Srabani Kar, et al.
Published: (2022)

Novel Anti-Cancer Stem Cell Compounds: A Comprehensive Review
by: Shanchun Guo, et al.
Published: (2024)

Getting hands on a drug for Covid-19: Inhaled and Intranasal Niclosamide
by: Karl Kunzelmann
Published: (2021)

Revisiting Niclosamide Formulation Approaches – a Pathway Toward Drug Repositioning
by: Jug M, et al.
Published: (2024)

The Impact of Polymers on Enzalutamide Solid Self-Nanoemulsifying Drug Delivery System and Improved Bioavailability
by: Su-Min Lee, et al.
Published: (2024)

Oral Delivery of Niclosamide as an Amorphous Solid Dispersion That Generates Amorphous Nanoparticles during Dissolution
by: Miguel O. Jara, et al.
Published: (2022)

YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy
by: Wing Lam, et al.
Published: (2023)

Antiandrogenic activity and bioavailability of magnolol analogs - A potential for prostate cancer therapeutics
by: Agneta Oskarsson, et al.
Published: (2023)

Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate Airways
by: Kent Miner, et al.
Published: (2019)

Predicting lung exposure of intramuscular niclosamide as an antiviral agent: Power‐law based pharmacokinetic modeling
by: Taeheon Kim, et al.
Published: (2024)

Niclosamide as a Repurposing Drug against <i>Corynebacterium striatum</i> Multidrug-Resistant Infections
by: Veronica Folliero, et al.
Published: (2022)

Hydrotalcite-Niclosamide Nanohybrid as Oral Formulation towards SARS-CoV-2 Viral Infections
by: Goeun Choi, et al.
Published: (2021)

Core Structure-Activity Relationship Studies of 5,7,20-<i>O</i>-Trimethylsilybins in Prostate Cancer Cell Models
by: Sitong Wu, et al.
Published: (2023)

Estrogens Modulate Somatostatin Receptors Expression and Synergize With the Somatostatin Analog Pasireotide in Prostate Cells
by: Valentina Rossi, et al.
Published: (2019)

The antiparasitic drug niclosamide inhibits dengue virus infection by interfering with endosomal acidification independent of mTOR.
by: Jo-Chi Kao, et al.
Published: (2018)

Exploring Structure-Activity Relationships of Niclosamide-Based Colistin Potentiators in Colistin-Resistant Gram-Negative Bacteria
by: Liam Berry, et al.
Published: (2024)

Amorphous Solid Dispersions and the Contribution of Nanoparticles to In Vitro Dissolution and In Vivo Testing: Niclosamide as a Case Study
by: Miguel O. Jara, et al.
Published: (2021)

Altered Gene Expression in the Schistosome-Transmitting Snail Biomphalaria glabrata following Exposure to Niclosamide, the Active Ingredient in the Widely Used Molluscicide Bayluscide.
by: Si-Ming Zhang, et al.
Published: (2015)

Corrigendum: Estrogens modulate somatostatin receptors expression and synergize with the somatostatin analog pasireotide in prostate cells
by: Valentina Rossi, et al.
Published: (2024)